drugset / Trial / NCT06891872

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine

NCT06891872

Phase 4 Not yet recruiting 720 enrolled Sinovac (Dalian) Vaccine Technology Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.

Timeline

Start
2025-05
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject DTaP vaccine Vaccine Intramuscular
Subject MMR vaccine Vaccine Subcutaneous
Subject Varicella vaccine Vaccine Subcutaneous